I'll research Baxter International (BAX) to build a comprehensive earnings preview. Let me start by gathering recent filings, transcripts, and news.Let me read the Q1 2026 earnings call and investigate that July 14 "release," plus pull recent news and filings.This is very helpful. Key insight: the July 14 document is a segment recast (new reporting basis). Let me gather stock price, recent news/press releases, 8-Ks, and the Q1 earnings release for additional context.The stock is up sharply into the print (~$21.7 to ~$24.8 in a week). Let me read the segment recast 8-K narrative and check recent news/analyst activity.Let me pull the Q1 press release for headline guidance/details and search the web for Q2 consensus estimates and any recent catalysts driving the pre-earnings rally.I now have a comprehensive picture. Let me compile a few price/performance stats before writing.# Baxter International (BAX) — Q2 2026 Earnings Preview
This is a "prove the second-half ramp" quarter. Baxter has told investors that H1 2026 will be pressured by known mechanical headwinds, with the recovery back-half loaded. Q2 is expected to be the trough of the year. The bar is low on the print itself, but the stock has run ~14% in the week into earnings and sits ~57% above its March low — so expectations have quietly reset higher, and the burden shifts to management's credibility on the 2H inflection and any update on the two big overhangs: the Novum IQ pump hold and the permanent CFO search.
This is critical for modeling. On July 14, 2026, Baxter recast its historicals: effective Q2 2026 it reports only two segments — Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST). The former standalone Pharmaceuticals segment has been folded into MPT, inside a renamed Infusion Therapies & Platforms (ITP) division (ITP now = the old Infusion Therapies & Technologies plus injectables, inhaled anesthesia, and drug compounding). Additionally, some corporate costs that were previously fully allocated to segments will now remain unallocated, which changes reported segment margins. - Watch: don't compare Q2 segment margins to old-basis models. On a recast basis, MPT posted ~$1.92B sales in Q1'26 and HST ~$705M. Q2'25 recast total company sales were ~$2.81B — the key top-line comp.
Full-year guidance (reiterated at Q1) is reported sales flat to +1%, organic ~flat, and adjusted EPS of $1.85–$2.05, with full-year adjusted operating margin of 13–14%. Management explicitly guided Q2 EPS to be "similar to Q1" (~$0.36) with only slight volume improvement, because the ITP absorption headwind is most pronounced in Q2. - The math is demanding: H1 adjusted EPS is tracking to roughly ~$0.73 (Q1 $0.36 + a Q2 in the ~$0.36–0.38 zone), which implies ~$1.22 of EPS in H2 at the midpoint — nearly double the H1 run-rate. - Management's bridge for the implied ~500 bps H1→H2 margin expansion: ~250 bps from volume leverage/seasonality, ~125 bps from cost actions ("largely complete"), and ~125 bps from rolling through high-cost 2025 inventory (which clears in Q2). - Watch: any wording that softens the 2H ramp — or any sign the Q2 absorption hit is worse than "trough" — would be the single biggest negative catalyst. Conversely, confidence signposts (order book, cost-action completion) support the guide.
Infusion Therapies & Platforms (new ITP, within MPT) - Novum IQ LVP shipment/installation hold remains the dominant swing factor. Guidance assumes the hold stays in place all year and bakes in potential customer returns, even though returns have been immaterial so far. Q2 is the last quarter before the Novum sales headwind laps. Any update on the hardware/software fix, regulatory refiling, or return activity is a catalyst either way. Management is leaning on the Spectrum LVP and newly launched Novum syringe pumps to defend the high-margin IV set/disposables base. - IV Solutions: management says clinical-practice changes created a "new baseline"; they expect this to normalize during 2026 (lapping the Hurricane Helene distributor build that inflated 1H'25). - Injectables & Anesthesia: the weak spot — down 13% organic in Q1 on supply constraints, premix softness, and IV-push utilization. A contract-manufacturer disruption is expected to constrain supply into 2027. Offset by Drug Compounding (+20% organic). - Advanced Surgery: the consistent bright spot (+10% organic in Q1, hemostats/sealants). Look for continued double-digit-ish growth.
Healthcare Systems & Technologies (HST) - HST was down 2% organic in Q1 (Front Line Care order timing + planned portfolio exits). Management expects low-single-digit HST growth for the year, back-half weighted, driven by new launches (Connex 360, Dynamo smart stretcher) and a "strong U.S. capital order book." Q2 will likely still be soft; the proof is the order-to-revenue conversion into H2. - Watch: any commentary on U.S. hospital capital-spending health — management says it has seen no slowdown yet, but flagged macro uncertainty.
Given the ~14% run into the print and BAX's track record of sharp post-earnings moves, an in-line quarter with an unchanged, back-half-dependent guide may not be enough to sustain the recent momentum — the market will want evidence the second-half acceleration is already visible in orders, costs, and cash.
Note: I was unable to retrieve live sell-side consensus estimates for the quarter, so the benchmarks above are anchored to management's own reiterated guidance and Q2 framework rather than to Street numbers.